Cargando…

Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance

BACKGROUND/AIMS: Elobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor, was recently launched in Japan for the treatment of chronic idiopathic constipation. We conducted an interim analysis of post-marketing surveillance to evaluate the safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Atsushi, Fujimaki, Mio, Arai, Yuki, Emori, Kento
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Neurogastroenterology and Motility 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274463/
https://www.ncbi.nlm.nih.gov/pubmed/35799237
http://dx.doi.org/10.5056/jnm20263
_version_ 1784745308851273728
author Nakajima, Atsushi
Fujimaki, Mio
Arai, Yuki
Emori, Kento
author_facet Nakajima, Atsushi
Fujimaki, Mio
Arai, Yuki
Emori, Kento
author_sort Nakajima, Atsushi
collection PubMed
description BACKGROUND/AIMS: Elobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor, was recently launched in Japan for the treatment of chronic idiopathic constipation. We conducted an interim analysis of post-marketing surveillance to evaluate the safety and efficacy of elobixibat in elderly patients with chronic constipation and compared the efficacy according to administration time. METHODS: Safety and efficacy outcomes were evaluated through patient interviews for 4 weeks. RESULTS: Adverse drug reactions (ADRs) were observed in 5.24% of the 1049 patients analyzed; diarrhea (2.19%) and abdominal pain (1.81%) were the most common. A serious ADR of death was reported in one patient (0.10%). The incidence of ADRs in the ≥ 65-year old or ≥ 75-year-old subpopulation was similar to that in the total patient population. Mean bowel movements per week significantly increased from 2.9 ± 2.5 at baseline to 5.0 ± 3.1 (P < 0.001) at Week 2 and 5.3 ± 2.6 (P < 0.001) at Week 4. The mean Bristol Stool Form Scale score significantly increased from 2.3 ± 1.4 at baseline to 3.8 ± 1.3 (P < 0.001) at Week 2 and 3.9 ± 1.1 at Week 4 (P < 0.001). Bowel movements significantly increased in the elderly population and subpopulations receiving elobixibat before breakfast, lunch, or dinner. The median time to bowel movement was 5 hours. Conclusion The results suggested that elobixibat was well-tolerated and efficacious in elderly patients with chronic constipation and can be administered before any meals.
format Online
Article
Text
id pubmed-9274463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Neurogastroenterology and Motility
record_format MEDLINE/PubMed
spelling pubmed-92744632022-07-30 Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance Nakajima, Atsushi Fujimaki, Mio Arai, Yuki Emori, Kento J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Elobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor, was recently launched in Japan for the treatment of chronic idiopathic constipation. We conducted an interim analysis of post-marketing surveillance to evaluate the safety and efficacy of elobixibat in elderly patients with chronic constipation and compared the efficacy according to administration time. METHODS: Safety and efficacy outcomes were evaluated through patient interviews for 4 weeks. RESULTS: Adverse drug reactions (ADRs) were observed in 5.24% of the 1049 patients analyzed; diarrhea (2.19%) and abdominal pain (1.81%) were the most common. A serious ADR of death was reported in one patient (0.10%). The incidence of ADRs in the ≥ 65-year old or ≥ 75-year-old subpopulation was similar to that in the total patient population. Mean bowel movements per week significantly increased from 2.9 ± 2.5 at baseline to 5.0 ± 3.1 (P < 0.001) at Week 2 and 5.3 ± 2.6 (P < 0.001) at Week 4. The mean Bristol Stool Form Scale score significantly increased from 2.3 ± 1.4 at baseline to 3.8 ± 1.3 (P < 0.001) at Week 2 and 3.9 ± 1.1 at Week 4 (P < 0.001). Bowel movements significantly increased in the elderly population and subpopulations receiving elobixibat before breakfast, lunch, or dinner. The median time to bowel movement was 5 hours. Conclusion The results suggested that elobixibat was well-tolerated and efficacious in elderly patients with chronic constipation and can be administered before any meals. The Korean Society of Neurogastroenterology and Motility 2022-07-30 2022-07-30 /pmc/articles/PMC9274463/ /pubmed/35799237 http://dx.doi.org/10.5056/jnm20263 Text en © 2022 The Korean Society of Neurogastroenterology and Motility https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Nakajima, Atsushi
Fujimaki, Mio
Arai, Yuki
Emori, Kento
Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance
title Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance
title_full Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance
title_fullStr Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance
title_full_unstemmed Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance
title_short Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance
title_sort safety and efficacy of elobixibat, an ileal bile acid transporter inhibitor, in elderly patients with chronic idiopathic constipation according to administration time: interim analysis of post-marketing surveillance
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274463/
https://www.ncbi.nlm.nih.gov/pubmed/35799237
http://dx.doi.org/10.5056/jnm20263
work_keys_str_mv AT nakajimaatsushi safetyandefficacyofelobixibatanilealbileacidtransporterinhibitorinelderlypatientswithchronicidiopathicconstipationaccordingtoadministrationtimeinterimanalysisofpostmarketingsurveillance
AT fujimakimio safetyandefficacyofelobixibatanilealbileacidtransporterinhibitorinelderlypatientswithchronicidiopathicconstipationaccordingtoadministrationtimeinterimanalysisofpostmarketingsurveillance
AT araiyuki safetyandefficacyofelobixibatanilealbileacidtransporterinhibitorinelderlypatientswithchronicidiopathicconstipationaccordingtoadministrationtimeinterimanalysisofpostmarketingsurveillance
AT emorikento safetyandefficacyofelobixibatanilealbileacidtransporterinhibitorinelderlypatientswithchronicidiopathicconstipationaccordingtoadministrationtimeinterimanalysisofpostmarketingsurveillance